Literature DB >> 10065878

Glucagon-like peptide-1 (7-36) amide as a novel neuropeptide.

E Blázquez1, E Alvarez, M Navarro, I Roncero, F Rodríguez-Fonseca, J A Chowen, J A Zueco.   

Abstract

Although earlier studies indicated that GLP-1 (7-36) amide was an intestinal peptide with a potent effect on glucose-dependent insulin secretion, later on it was found that several biological effects of this peptide occur in the brain, rather than in peripheral tissues. Thus, proglucagon is expressed in pancreas, intestine, and brain, but post translational processing of the precursor yields different products in these organs, glucagon-like peptide-1 (7-36) amide being one of the forms produced in the brain. Also, GLP-1 receptor cDNA from human and rat brains has been cloned and sequenced, and the deduced amino acid sequences are the same as those found in pancreatic islets. Through these receptors, GLP-1 (7-36) amide from gut or brain sources induces its effects on the release of neurotransmitters from selective brain nuclei, the inhibition of gastric secretion and motility, the regulation of food and drink intake, thermoregulation, and arterial blood pressure. Central administration (icv) of GLP-1 (7-36) amide produces a marked reduction in food and water intake, and the colocalization of the GLP-1 receptor, GLUT-2, and glucokinase mRNAs in hypothalamic neurons involved in glucose sensing suggests that these cells may be involved in the transduction of signals needed to produce a state of fullness. In addition, GLP-1 (7-36) amide inhibits gastric acid secretion and gastric emptying, but these effects are not found in vagotomized subjects, suggesting a centrally mediated effect. Similar results have been found with the action of this peptide on arterial blood pressure and heart rate in rats. Synthesis of GLP-1 (7-36) amide and its own receptors in the brain together with its abovementioned central physiological effects imply that this peptide may be considered a neuropeptide. Also, the presence of GLP-1 (7-36) amide in the synaptosome fraction and its calcium-dependent release by potassium stimulation, suggest that the peptide may act as a neurotransmitter although further electrophysiological and ultrastructural studies are needed to confirm this possibility.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10065878     DOI: 10.1007/bf02914270

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  67 in total

1.  Distribution and molecular forms of glucagon-like peptide in the dog.

Authors:  K Suda; H Takahashi; N Fukase; H Manaka; M Tominaga; H Sasaki
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

Review 2.  Central representation of visceral function.

Authors:  D F Cechetto
Journal:  Fed Proc       Date:  1987-01

3.  Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats.

Authors:  M Tang-Christensen; P J Larsen; R Göke; A Fink-Jensen; D S Jessop; M Møller; S P Sheikh
Journal:  Am J Physiol       Date:  1996-10

4.  Analysis of upstream glucokinase promoter activity in transgenic mice and identification of glucokinase in rare neuroendocrine cells in the brain and gut.

Authors:  T L Jetton; Y Liang; C C Pettepher; E C Zimmerman; F G Cox; K Horvath; F M Matschinsky; M A Magnuson
Journal:  J Biol Chem       Date:  1994-02-04       Impact factor: 5.157

5.  Human glucagon-like peptides 1 and 2 activate rat brain adenylate cyclase.

Authors:  N M Hoosein; R S Gurd
Journal:  FEBS Lett       Date:  1984-12-03       Impact factor: 4.124

6.  Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.

Authors:  B Thorens
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

7.  Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides.

Authors:  K Hupe-Sodmann; G P McGregor; R Bridenbaugh; R Göke; B Göke; H Thole; B Zimmermann; K Voigt
Journal:  Regul Pept       Date:  1995-08-22

8.  Hamster preproglucagon contains the sequence of glucagon and two related peptides.

Authors:  G I Bell; R F Santerre; G T Mullenbach
Journal:  Nature       Date:  1983-04-21       Impact factor: 49.962

9.  Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.

Authors:  J Eng; W A Kleinman; L Singh; G Singh; J P Raufman
Journal:  J Biol Chem       Date:  1992-04-15       Impact factor: 5.157

10.  Stimulation of truncated glucagon-like peptide-1 release from the isolated perfused canine ileum by glucose absorption.

Authors:  K Sugiyama; H Manaka; T Kato; K Yamatani; M Tominaga; H Sasaki
Journal:  Digestion       Date:  1994       Impact factor: 3.216

View more
  5 in total

1.  Glucagon-like peptide 1 (GLP-1) can reverse AMP-activated protein kinase (AMPK) and S6 kinase (P70S6K) activities induced by fluctuations in glucose levels in hypothalamic areas involved in feeding behaviour.

Authors:  Verónica Hurtado-Carneiro; Carmen Sanz; Isabel Roncero; Patricia Vazquez; Enrique Blazquez; Elvira Alvarez
Journal:  Mol Neurobiol       Date:  2012-02-05       Impact factor: 5.590

2.  Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.

Authors:  Claude Knauf; Patrice D Cani; Christophe Perrin; Miguel A Iglesias; Jean François Maury; Elodie Bernard; Fadilha Benhamed; Thierry Grémeaux; Daniel J Drucker; C Ronald Kahn; Jean Girard; Jean François Tanti; Nathalie M Delzenne; Catherine Postic; Rémy Burcelin
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 3.  Significance of Brain Glucose Hypometabolism, Altered Insulin Signal Transduction, and Insulin Resistance in Several Neurological Diseases.

Authors:  Enrique Blázquez; Verónica Hurtado-Carneiro; Yannick LeBaut-Ayuso; Esther Velázquez; Luis García-García; Francisca Gómez-Oliver; Juan Miguel Ruiz-Albusac; Jesús Ávila; Miguel Ángel Pozo
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-09       Impact factor: 6.055

4.  Neonatal exendin-4 treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine growth-retarded rats.

Authors:  Elisabeth L Raab; Patricia M Vuguin; Doris A Stoffers; Rebecca A Simmons
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-10-21       Impact factor: 3.619

Review 5.  Preventing Oxidative Stress in the Liver: An Opportunity for GLP-1 and/or PASK.

Authors:  Verónica Hurtado-Carneiro; Pilar Dongil; Ana Pérez-García; Elvira Álvarez; Carmen Sanz
Journal:  Antioxidants (Basel)       Date:  2021-12-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.